Business
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment
About this update from Nextcure, Inc.
[{"type":"text","content":"LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported second-quarter 2024 financial results. “Following the release of Phase 1b data for the combination of NC410 and pembrolizumab at ASCO, we have completed enrollment of additional ovarian cancer patients, and we look forward to sharing results from the expanded ovarian cohort later this year,” said Michael Richman, president and CEO of NextCure. “We also continue to make important progress with our promising B7-H4 antibody-drug conjugate program, LNCB74, including the completion of GLP toxicology studies in July. We remain on track to submit an IND filing by year-end and rapidly advance into clinical development. NextCure is well capitalized to continue executing on our strategic priorities, with cash reserves expected to fund operations into the second half of 2026.” Business Highlights and Near-Term Milestones NC410 (LAIR-2 fusion) Completed enrollment in June 2024 of an additional 16 ovarian cancer patients among the 100 mg and 200 mg cohorts of the Phase 1b portion of a Phase 1b/2 study evaluating NC410 in combination with pembrolizumab (pembro) in colorectal cancer (CRC) and ovarian cancer patients.Clinical data from the Phase 1b portion of the trial was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024.On track to present data from ongoing ovarian cancer cohort expansion along with an update on the CRC data in the fourth quarter of 2024. LNCB74 (B7-H4 ADC) Recently completed GLP toxicology studies.Presented a poster highlighting strong safety and pharmacokinetic profiles for LNCB74 at the 2024 American Association for Cancer Research (AACR) Annual Meeting.Planned submission of an Investigational New Drug (IND) application by year-end. NC181 (APOE4) Presented “NC181: First-in-class Approach to Treat Alzheimer’s Disease” at the H.C. Wainwright 5th Annual Neuro Perspectives...